Eisai Co., Ltd. (OTCPK:ESALF) Q1 2026 Earnings Conference Call August 5, 2025 2:30 AM ET
Company Participants
a – Corporate Participant
Hideki Toyosaki – Corporate Participant
Katsutoshi Ido – VP, Chief Scientific Officer & Head of DHBL Discoverry
Katsuya Haruna – Group Officer & Executive VP of LENVIMA & Oncology Pipeline Global Lead and US Business Operations
Keisuke Naito – Representative Corporate Officer, EVP, COO & Chief Growth Officer
Lynn D. Kramer – VP & Chief Clinical Officer
Sayoko Sasaki – Corporate Participant
Tatsuyuki Yasuno – Senior VP & President of Americas Region
Terushige Iike – Executive VP, Rep. Corporate Officer and Chief IR Officer & Business Officer
Toshihiko Yusa – Corporate Participant
Conference Call Participants
Fumiyoshi Sakai – UBS Investment Bank, Research Division
Hidemaru Yamaguchi – Citigroup Inc., Research Division
Miki Sogi – Sanford C. Bernstein & Co., LLC., Research Division
Seiji Wakao – JPMorgan Chase & Co, Research Division
Shinichiro Muraoka – Morgan Stanley, Research Division
Tony Ren – Macquarie Research
Operator
[Interpreted] Thank you very much for taking your time to join the financial results presentation by Eisai Company Limited. It is now time. We would like to start the financial results presentation session for Q1 fiscal 2025. Today, it will be held in a virtual format. Please download or look at the slides for the presentation on our website. Let me introduce the presenter today, Mr. Keisuke Naito, Representative Corporate Officer, Executive Vice President, COO and Chief Growth Officer. Over to you, Mr. Naito.
Keisuke Naito
[Interpreted] Thank you very much for joining us today for our earnings call for the first quarter of fiscal year 2025. I am Keisuke Naito, COO and Chief Growth Officer. With many companies reporting their earnings around the same time, we have decided to hold this conference call entirely remotely in order to take into
#Eisai #ESALF #Earnings #Call #Transcript